Login to Your Account

Precision Ocular lands £15.5M to develop more precise eye drugs, delivery

By Nuala Moran
Staff Writer

Wednesday, July 20, 2016

LONDON – Precision Ocular Ltd. closed a £15.5 million (US$20.4 million) series A funding that will enable it to take the first of new generation of low-dose, slow-release retinal drugs from preclinical research and into the clinic.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription